AstraZeneca plc (ADR) (AZN) is Upgraded by Jefferies to Buy

AstraZeneca plc (ADR) (AZN) was Upgraded by Jefferies to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Jefferies advised their investors in a research report released on Sep 12, 2016.

Many Wall Street Analysts have commented on AstraZeneca plc (ADR). AstraZeneca plc (ADR) was Upgraded by Jefferies to ” Buy” on Sep 12, 2016. AstraZeneca plc (ADR) was Upgraded by Argus to ” Buy” on Aug 29, 2016. AstraZeneca plc (ADR) was Initiated by Argus to “Hold” on Jul 12, 2016.

On the company’s financial health, AstraZeneca plc (ADR) reported $0.83 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.83. The company had revenue of $5603.00 million for the quarter, compared to analysts expectations of $5596.35 million. The company’s revenue was down -4.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.21 EPS.

AstraZeneca plc (ADR) opened for trading at $33.07 and hit $33.21 on the upside on Wednesday, eventually ending the session at $33.18, with a gain of 0.27% or 0.09 points. The heightened volatility saw the trading volume jump to 4,487,444 shares. Company has a market cap of $83,945 M.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).

AstraZeneca plc (ADR)

Leave a Reply

AstraZeneca plc (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on AstraZeneca plc (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.